A randomized controlled trial of hydroxychloroquine prophylaxis for Healthcare Workers exposed to COVID-19

Conditions

None listed

Bharath Kumar Tirupakuzhi Vijayaraghavan, Vivekanand Jha, Dorrilyn Rajbhandari, Sheila Nainan Myatra, Arpita Ghosh et al. (21 authors)

BMJ Open2022-06-0111 citations

10.1136/bmjopen-2021-059540

Expert consensus statements for the management of COVID-19-related acute respiratory failure using a Delphi method.

Nasa P, Azoulay E, Khanna AK, Jain R, Gupta S, Javeri Y, Juneja D, Rangappa P, Sundararajan K, Alhazzani W, Antonelli M, Arabi YM, Bakker J, Brochard LJ, Deane AM, Du B, Einav S, Esteban A, Gajic O, Galvagno SM, Guérin C, Jaber S, Khilnani GC, Koh Y, Lascarrou JB, Machado FR, Malbrain MLNG, Mancebo J, McCurdy MT, McGrath BA, Mehta S, Mekontso-Dessap A, Mer M, Nurok M, Park PK, Pelosi P, Peter JV, Phua J, Pilcher DV, Piquilloud L, Schellongowski P, Schultz MJ, Shankar-Hari M, Singh S, Sorbello M, Tiruvoipati R, Udy AA, Welte T, Myatra SN.

2021-03-16125 citations

10.1186/s13054-021-03491-y

Hydroxychloroquine plus personal protective equipment versus standard personal protective equipment alone for the prevention of COVID-19 infections among frontline healthcare workers: the HydrOxychloroquine Prophylaxis Evaluation(HOPE) trial: A structured summary of a study protocol for a randomized controlled trial.

Tirupakuzhi Vijayaraghavan BK, Jha V, Rajbhandari D, Myatra SN, John O, Ghosh A, Bassi A, Arfin S, Kunigari M, Joshi R, Donaldson L, Hammond N, Venkatesh B, HOPE investigators.

2020-08-318 citations

10.1186/s13063-020-04679-3

Interventions

Intervention1: hydroxychloroquine along with Standard care Personal protective equipment: 800 mg of hydroxychloroquine on the day of enrollment and 400mg once a week after that for a total of 12 weeks

Eligibility

Inclusion criteria

Inclusion criteria: All HCWs directly exposed to confirmed COVID-19 patients.

Exclusion criteria

Exclusion criteria: Participants who meet any of following criteria will be are excluded 1. have a proven diagnosis of COVID-19 infection 2. are currently taking chloroquine or HCQ 3. are pregnant 4. are breast feeding 5. known QT prolongation 6. history of serious cardiac dysrhythmias or cardiomyopathy 7. have maculopathy of the eye (a contra-indication to HCQ) 8. are immunocompromised because of a disease or therapy 9. pregnant women

Design outcomes

Primary

Measure	Time frame
Proportion of laboratory confirmed symptomatic COVID-19 cases between the groups at the end of 6 monthsTimepoint: Proportion of laboratory confirmed symptomatic COVID-19 cases between the groups at the end of 6 months	—

Secondary

Measure	Time frame
1. hospitalization due to suspected COVID-19 disease, 2. admission with suspected COVID-19 to either an ICU or HDU , 3. all-cause mortality, 4.organ failure 5. duration of ICU or HDU stay, 6. Need for vasopressors 7. Need for renal replacement 8. duration of hospitalization, 9. readmission to hospital 10.days off workTimepoint: From randomization till the study end	—

Countries

India

Contacts

Public ContactProfessor Vivekanand Jha

The George Institute for Global Health, India

vjha@georgeinstitute.org.in911141588091

Outcome results